Mironid is a biotechnology company that focuses on developing a new class of targeted therapies aimed at treating diseases associated with dysregulated protein degradation. The company utilizes its proprietary technology platform to identify and optimize small molecule drug candidates that can modulate the ubiquitin-proteasome system.